Leukemia lymphoma cancer News
recent headlines ...
U.S FDA Grants Pralatrexate Orphan Drug Designation For The Treatment Of...
Allos Therapeutics, Inc. (Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to the Company's novel antifolate, pralatrexate (PDX), for the treatment of patients with follicular lymphoma.
Source: Medical News Today (Tue, 02 Dec 2008 17:22:13 GMT)
03.12.2008 - DJ HUGIN NEWS/Micromet, Inc. to Host Webcast and Conference Call...
Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. =--------------------------------------------------------------------- =-------------
Source: 4investors (Wed, 03 Dec 2008 12:46:59 GMT)
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in...
Rigel Pharmaceuticals, Inc. today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008, at 4:00 p.m.
Source: PR Newswire via Yahoo! Finance (Wed, 03 Dec 2008 12:30:00 GMT)
Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer...
SOUTH SAN FRANCISCO, Calif., Dec. 1, 2008 -- Hana Biosciences , a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that several presentations related to the Company's lead anti-cancer compound, Marqibo (vincristine sulfate injection, OPTISOME), will be presented at the upcoming annual meeting of the American Society of Hematology in San Francisco ...
Source: GlobeNewswire via Yahoo! Finance (Mon, 01 Dec 2008 12:30:00 GMT)
Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data...
Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a webcast and conference call on, Monday, December 8, 2008, at 2:00 p.m.
Source: PR Newswire via Yahoo! Finance (Wed, 03 Dec 2008 12:00:00 GMT)
St. Jude Identifies Genomic Causes Of A Certain Type Of Leukemia Relapse ...
Scientists at St. Jude Children's Research Hospital have identified distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse. The finding offers a pathway to designing treatments for ALL relapse in children and, ultimately, in adults. The most common childhood cancer, ALL affects thousands of children annually in the United States.
Source: Medical News Today (Fri, 28 Nov 2008 13:05:01 GMT)
FDA accepts Zevalin supplemental biologics license application ...
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line ...
Source: News-Medical-Net (Tue, 02 Dec 2008 10:59:29 GMT)
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be...
Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML --
Source: PR Newswire via Yahoo! Finance (Mon, 01 Dec 2008 13:00:00 GMT)
Genes May Predict Lymphoma Treatment Outcome ...
WEDNESDAY, Nov. 26 (HealthDay News) -- Gene activity patterns can tell doctors whether people with a certain type of non-Hodgkin lymphoma have a better chance of survival with treatment, according to a new study.
Source: HealthDay via Yahoo! News (Wed, 26 Nov 2008 22:03:07 GMT)
Micromet Expands Committed Equity Financing Facility to $75 Million ...
Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has entered into an agreement expanding its Committed Equity Financing Facility with Kingsbridge Capital Limited, a private investment group.
Source: PR Newswire via Yahoo! Finance (Tue, 02 Dec 2008 12:00:00 GMT)
© 2007 citedlive.com - all rights reserved